Argenx公司2025年财报显示,全年营收达42.48亿美元,首次实现盈利,其中艾加莫德(商品名:VYVGART)销售额为41.51亿美元,同比增长90%。艾加莫德是一种人IgG1抗体片段,通过结合新生儿Fc受体(FcRn)降低循环IgG自身抗体水平,是首个获批的FcRn拮抗剂,已在全球范围内获批用于治疗全身型重症肌无力(gMG)、慢性炎症性脱髓鞘性多发性神经病(CIDP),并在日本获批用于...
Source LinkArgenx公司2025年财报显示,全年营收达42.48亿美元,首次实现盈利,其中艾加莫德(商品名:VYVGART)销售额为41.51亿美元,同比增长90%。艾加莫德是一种人IgG1抗体片段,通过结合新生儿Fc受体(FcRn)降低循环IgG自身抗体水平,是首个获批的FcRn拮抗剂,已在全球范围内获批用于治疗全身型重症肌无力(gMG)、慢性炎症性脱髓鞘性多发性神经病(CIDP),并在日本获批用于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.